echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The first bevacizumab bioequivalent drug approved for marketing in China

    The first bevacizumab bioequivalent drug approved for marketing in China

    • Last Update: 2019-12-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The sales of gold in the dishonesty punishment system set up by the health insurance bureau is a key task The four cities have purchased the conventional operation in Jiangsu Province with the volume The domestic independent R & D innovative drugs are expected to upgrade the "cocktail" therapy The latest progress of heavy drugs such as AstraZeneca, Roche, Johnson & Johnson, etc at the ash annual meeting is coming out Daily fresh medicine news, speed reading club and you pay attention to! On June 6, according to the information of the health care Commission, in order to implement the relevant requirements of documents such as the guidance on carrying out the pilot work of formulating the hospital's articles of Association (Guo Wei ban Yi Fa [2018] No 12), the health care Commission formulated the model articles of Association of public hospitals It is required that the health and Health Committee of each province, autonomous region, municipality directly under the central government and Xinjiang production and Construction Corps shall implement 12000 medical equipment representatives of public hospitals are about to start strict investigation and introduce face recognition, big data analysis, AI and other technologies (cypress blue instrument) A seminar led by the state health insurance bureau was held in Beijing on the 6th The main content of the meeting is "drug kickbacks and gold sales problems that have been hard to return in the field of pharmaceutical purchase and sale for a long time" In response to these problems, the Medical Insurance Bureau commissioned Beijing University to carry out relevant research Through the construction plan of two parts of the credit evaluation system and the dishonesty punishment system, the drug rebate was associated with illegal punishment, drug bidding and purchase, and drug price (e drug manager) On June 6, the medical insurance bureau issued the opinions on the current drug price management, which clearly defined the scope of drug price management by the medical security department, including chemical drugs, proprietary Chinese medicine, biochemical drugs, Chinese herbal pieces, medical institution preparations, etc Among them, the price of narcotic drugs and the first category of psychotropic drugs shall be guided by the government, and the price of other drugs shall be regulated by the market (pharmacy manager) Recently, the health and Health Commission issued the notice on printing and distributing the model articles of association of public hospitals, which shows that the model articles of association of public hospitals have been formulated to guide the hospital to carry out the formulation of the articles of association in a scientific and standardized way, and to successfully complete the objectives of the formulation of the articles of association, so as to provide references for all regions in promoting the formulation of the articles of association of public hospitals On the same day, the national health insurance bureau made a binding action to curb kickbacks, and both of them sounded an alarm to all dealers, agents and pharmaceutical representatives in the pharmaceutical industry (cypress blue) Recently, the health and Health Commission issued the notice on printing and distributing guidelines for the construction and management of geriatric medicine (for Trial Implementation), which clearly states that the geriatric medicine department must be set up in the second level and above general hospitals with conditions As the construction of geriatrics department is put on the agenda, medical personnel are also facing new development opportunities (grassroots doctors' commune) Hubei Provincial Food and Drug Administration recently issued the notice on standardizing the supervision and management of the business license of drug retail chain enterprises (Draft for comments) The notice pointed out that for the newly established drug retail chain enterprises, the headquarters can designate a manager with the qualification of licensed pharmacist to act as the enterprise head of the subordinate stores, or the manager registered in the subordinate stores The pharmacist is in charge of our store (pharmacy manager) On June 6, the Procurement Alliance of Changzhou City, Lianyungang City, Yangzhou City and Zhenjiang City in Jiangsu Province released the announcement on centralized procurement of medical consumables alliance of public hospitals in Changzhou City, Lianyungang City, Yangzhou City and Zhenjiang city According to the announcement, the four city alliance will jointly carry out the volume purchase of four kinds of medical consumables: disposable laryngeal mask, disposable intravenous indwelling needle, disposable precision infusion set, breast circumcision puncture needle and accessories The issuance of the volume purchasing documents of the four cities alliance means that the volume purchasing of 13 cities in Jiangsu Province has been fully implemented! (cypress blue instrument) Recently, bevacizumab injection developed by Qilu Pharmaceutical Co., Ltd (trade name: antake) was approved for listing and registration, the website of the State Food and Drug Administration announced Tuesday It is the first biologically similar bevacizumab approved in China It is mainly used for the treatment of patients with advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal cancer (Sina Medical News) Recently, azfuding is the first one in China to have independent intellectual property rights, obtain the support of the national "major new drug creation" science and technology major special project, and is applying for listing in advance with phase II clinical data Phase III clinical trials will be carried out soon, which is expected to end the 30-year non innovative drug listing situation in this field (biological exploration) On December 7-10, the 61st annual meeting of the American Society of Hematology (ash2019) was held in Orlando, Florida, USA at the meeting, a number of pharmaceutical companies announced their latest progress in anticancer drugs For example, AstraZeneca published all the results of the phase III clinical study of the BTK inhibitor, calvance TN, Roche published the new data of two new cd20-cd3 T cells combined with bispecific antibodies mosunetuzumab and cd20-tcb in the treatment of relapsed or refractory non Hodgkin's lymphoma, Johnson & Johnson published the new data of BCMA Preliminary results of stage Ib / II cartitude-1 study of car-t therapy jnj-4528 for recurrent or refractory multiple myeloma (Sina Medical News) The world's first tumor targeting IL-15 fusion protein (bj-001), which is independently developed and has a global patent, has successfully completed the first patient's first drug administration on December 4, 2019 at the next oncology clinical center in San Antonio, Texas, USA At present, all patients are normal (American news agency) Recently, gene therapy company fergene announced that the main clinical end point of gene therapy, nadofaragene firetenovec, was reached in the three-stage clinical trial for advanced non myometrial invasive bladder cancer patients with poor response to BCG Nadofaragene fireadenovec is a kind of gene therapy based on adenovirus vector It needs to deliver adenovirus vector containing interferon α - 2b gene to bladder through catheter perfusion every three months (yaomingkant) On July 7, the second indication of lovatinib (acceptance No.: jxhs1900157, jxhs1900158) submitted an application for listing to CDE and was accepted In addition, the combination therapy of lovatinib and K drugs has carried out the first-line clinical trials of endometrial cancer, NSCLC and liver cancer in China, all of which have entered the third stage (CPHI Pharma online)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.